ロード中...
Development of oral immunomodulatory agents in the management of multiple sclerosis
The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3100222/ https://ncbi.nlm.nih.gov/pubmed/21625416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S10498 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|